Our very own Ulrica Slåne Bjerke was today interviewed by EFN talking about a very positive January performance in the healthcare and biotech sector. In Børslunch, Ulrica talks about companies like Eli Lilly, Loxo, Gilead and Nordic Nanovector along with Mårten Steen from Healthcap.
In Swedish only.
Arctic Aurora LifeScience is an equity fund investing in global biotechnology and pharmaceutical companies. The fund is run by former portfolio manager in the Swedish Governmental Pension Fund AP3, Ulrica Bjerke, as well as Dr. Torbjørn Bjerke, both with 20 years of experience from the market. Arctic Aurora LifeScience was launched in May 2016 with both hedged and un-hedged share classes.
Past performance in Arctic Aurora LifeScience is no guarantee for future returns. Future returns depend on the market, fund manager skill, fund risk level, costs, among others. Performance in the fund may at times be negative and may for this fund vary considerably within periods.